Abstract:Background: Clostridioides difficile ( C . difficile ) is a spore-forming bacterial species that ubiquitously exists in the environment. Colonization by C. difficile is highly prevalent in infants, while fewer than 5% of adults are asymptomatic carriers. Disruption of the microbiome, such as through antibiotic treatment, triggers the germination of bacterial spores into numerous vegetative cells. These cells then produce enterotoxins that result in watery diarrhea and colonic inflammation. If left untreated, C. difficile infection (CDI) can lead to pseudomembranous colitis with the potentially life-threatening complication of toxic megacolon. Summary: Over the past few decades, the incidence, morbidity, and mortality associated with CDIs have increased. They have emerged as the primary cause of nosocomial gastrointestinal infections in industrialized countries, posing a significant burden on healthcare systems. Despite antibiotics often being the cause of CDIs, they remain the standard treatment. However, a considerable number of patients treated with antibiotics will experience recurrent CDI (rCDI). Microbiota-based therapies targeting the core issue of CDI – antibiotic-induced dysbiosis – hold promise for rCDI treatment. While data for probiotics are insufficient, numerous studies have highlighted the effectiveness of fecal microbiota transplantation (FMT) as a safe and viable therapeutic option for rCDI. This approach is now endorsed by multiple guidelines. Nonetheless, regulatory prerequisites, such as comprehensive stool donor screening, restrict the widespread adoption of FMT beyond specialized centers. Recently, the US Food and Drug Administration has approved two commercial microbiota-based therapeutics to prevent CDI recurrence. These therapeutics are available by prescription in the USA. RBX2660 (REBYOTATM) comprises a diverse consortium of live microbes derived from human stool and is administered via enema. On the other hand, SER-109 (VOWSTTM) is an orally administered spore-based medication. In this review, we discuss the potential of microbiota-based treatments for rCDI against the background of medico-legal challenges associated with classical FMT. Key Messages: FMT has emerged as a highly effective cure for rCDI. Nonetheless, regulatory prerequisites and laborious preparation procedures impede its widespread use. The establishment of ready-to-use microbiota-based therapeutics in clinical practice is necessary. In the USA, the recent approval of the first two commercial medications, including a spore-based oral preparation, marks a significant step forward.

[Advances in the treatment of Clostridium difficile infection in children]

A Multifaced Aspect of Clostridium difficile Infection in Pediatric Patients with Inflammatory Bowel Disease: Case Series and Literature Review

Molecular Characterization and Antibiotic Resistance of Clostridioides Difficile in Patients with Inflammatory Bowel Disease from Two Hospitals in China

Impacts of Infection with Different Toxigenic Clostridium Difficile Strains on Faecal Microbiota in Children.

Clostridioides difficile Infections: Prevention and Treatment Strategies

Epidemiological and clinical characteristics of Clostridium difficile infection in patients with refractory inflammatory bowel disease

Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population

The Evaluation of Fecal Microbiota Transplantation Vs Vancomycin in a Clostridioides Difficile Infection Model.

Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children

Therapeutics involved in managing initial and recurrent Clostridium difficile infection: An updated literature review

Controversies in the Prevention and Treatment of Clostridioides difficile Infection in Adults: A Narrative Review

Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies

Gut Microbial and Metabolic Features Associated With Clostridioides difficile Infection Recurrence in Children

Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection

What nurses need to know about fecal microbiota transplantation: education, assessment, and care for children and young adults

Current international and national clinical guidelines for the prevention, diagnosis, and treatment of Clostridioides difficile infection in adults and children: an overview, criticisms, and applicability in real-life clinical practice

Clostridioides Difficile: A Concise Review of Best Practices and Updates

Epidemiologic and Clinical Characteristics and Risk Factors for Severe Community-acquired Clostridium difficile Infection in Children

Advances in Therapeutic Strategies for the Management of Clostridioides difficile Infection

Fecal microbiota transplantation in gastrointestinal diseases: what practicing physicians should know

Guideline for the management of Clostridioides difficile infection in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2024 update